1 citations
,
November 2018 in “immuneACCESS” This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.
4 citations
,
June 2025 in “Cell Reports” In this study using the C3H/HeJ mouse model of alopecia areata, researchers found that hyperexpanded CD8+ T cell clones were sufficient to initiate disease, establishing a causal link between T cell clonality and pathogenicity.
May 2018 in “White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)” In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.
46 citations
,
October 2018 in “JCI insight” In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.
